000 | 04409nam a22005295i 4500 | ||
---|---|---|---|
001 | 978-3-030-02505-2 | ||
003 | DE-He213 | ||
005 | 20210201191345.0 | ||
007 | cr nn 008mamaa | ||
008 | 181211s2018 gw | s |||| 0|eng d | ||
020 |
_a9783030025052 _9978-3-030-02505-2 |
||
050 | 4 | _aRC261-271 | |
072 | 7 |
_aMJCL _2bicssc |
|
072 | 7 |
_aMED062000 _2bisacsh |
|
072 | 7 |
_aMJCL _2thema |
|
082 | 0 | 4 |
_a614.5999 _223 |
245 | 1 | 0 |
_aImmunotherapy _h[electronic resource] / _cedited by Aung Naing, Joud Hajjar. |
250 | _a2nd ed. 2018. | ||
264 | 1 |
_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2018. |
|
300 |
_aVIII, 182 p. 12 illus., 8 illus. in color. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_atext file _bPDF _2rda |
||
490 | 1 |
_aAdvances in Experimental Medicine and Biology, _x0065-2598 ; _v995 |
|
500 | _aAcceso multiusuario | ||
505 | 0 | _aOverview of Basic Immunology and Translational Relevance for Clinical Investigators -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: A New Age in cancer treatment -- Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice -- Skin Reactions to Immune Checkpoint Inhibitors -- Immune-related Adverse Events: Pneumonitis -- Immune checkpoint inhibitors-induced colitis -- Immune checkpoint inhibitors-induced hepatitis -- Symptoms as patient-reported outcomes in cancer patients undergoing immunotherapies . | |
520 | _aThe second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions. Edited by two renowned experts in the field, the book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science. | ||
541 |
_fUABC ; _cTemporal ; _d01/01/2021-12/31/2023. |
||
650 | 0 | _aCancer research. | |
650 | 1 | 4 |
_aCancer Research. _0https://scigraph.springernature.com/ontologies/product-market-codes/B11001 |
700 | 1 |
_aNaing, Aung. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
700 | 1 |
_aHajjar, Joud. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
710 | 2 | _aSpringerLink (Online service) | |
773 | 0 | _tSpringer Nature eBook | |
776 | 0 | 8 |
_iPrinted edition: _z9783030025045 |
776 | 0 | 8 |
_iPrinted edition: _z9783030025069 |
776 | 0 | 8 |
_iPrinted edition: _z9783030378561 |
830 | 0 |
_aAdvances in Experimental Medicine and Biology, _x0065-2598 ; _v995 |
|
856 | 4 | 0 |
_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=https://doi.org/10.1007/978-3-030-02505-2 |
912 | _aZDB-2-SBL | ||
912 | _aZDB-2-SXB | ||
942 | _cLIBRO_ELEC | ||
999 |
_c242539 _d242538 |